Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies

阿哌沙班 医学 华法林 内科学 心房颤动 终末期肾病 置信区间 相对风险 冲程(发动机) 荟萃分析 外科 血液透析 拜瑞妥 机械工程 工程类
作者
Konstantinos Zagoridis,Lazaros Karatisidis,Theodoros Mprotsis,Aikaterini Pentidou,Zoi Bezirgianidou,Christina Misidou,Emmanouil Spanoudakis
出处
期刊:Thrombosis Research [Elsevier BV]
卷期号:231: 17-24 被引量:6
标识
DOI:10.1016/j.thromres.2023.09.005
摘要

Optimal anticoagulation in patients with end-stage renal disease ESRD is a matter of debate since these patients are not included in randomized controlled trials (RCTs). Evolving data are in favor of apixaban compared to warfarin. Methods We extracted data from 2 RCTs, 5 retrospective cohort studies and 3 large data-based studies. Both dosing regimens of apixaban, standard or reduced, were accepted. In most studies characteristics of patients were balanced between arms. Patients with either atrial fibrillation (AF) or venous thromboembolism (VTE) were included. Quality of studies was graded as high and the funnel plot did not detect any publication bias. In total we analyzed the outcome of 6693 ESRD patients treated with apixaban and 19,836 treated with warfarin. Our analysis was performed by using the random effects model. We report our data as Risk Ratio (RR) and associated 95 % confidence interval values (95 %, CI). Results The RR (95 % CI) of major bleeding was 0.69 (0.57–0.84) p = 0.0002 in favor of apixaban vs warfarin with heterogeneity to be statistically significant I2 63% p = 0.004. Meta-regression analysis with year of publication as moderator shows in bubble plotting that studies published earlier than 2018 were plotted as outliers. The RR (95 % CI) of clinically relevant non-major bleeding (CRNMB) was 0.74 (0.64–0.87) p = 0.0002 favoring again apixaban. Standard apixaban dose over reduced dose is less hemorrhagic compared to warfarin. Overall, in our study the risk of thrombosis in both arms was statistically non-different. Conclusions In our study we observed less hemorrhagic events with apixaban in ESRD patients compared to warfarin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tina完成签到,获得积分10
1秒前
Lrcx完成签到 ,获得积分10
8秒前
涩费爱完成签到 ,获得积分10
9秒前
无限的丸子曾完成签到 ,获得积分10
10秒前
苗条的巧凡完成签到,获得积分10
14秒前
XiaohuaTu完成签到 ,获得积分10
14秒前
15秒前
假真真完成签到 ,获得积分10
16秒前
清淮完成签到 ,获得积分10
16秒前
夏安完成签到,获得积分10
16秒前
柿子完成签到,获得积分10
18秒前
悦耳的保温杯完成签到 ,获得积分10
21秒前
淮安石河子完成签到 ,获得积分10
22秒前
22秒前
水water完成签到 ,获得积分10
23秒前
23秒前
waveless完成签到,获得积分10
24秒前
yy完成签到,获得积分10
25秒前
zhangnan完成签到 ,获得积分10
25秒前
Sweet完成签到 ,获得积分10
27秒前
愛愛愛愛完成签到,获得积分10
27秒前
tanjuan发布了新的文献求助10
29秒前
彳亍宣完成签到 ,获得积分10
31秒前
嗡嗡声完成签到 ,获得积分10
34秒前
35秒前
茄子回锅肉完成签到,获得积分10
36秒前
姚怜南完成签到,获得积分10
37秒前
忧心的藏鸟完成签到 ,获得积分10
37秒前
飞飞完成签到,获得积分10
39秒前
沐野完成签到 ,获得积分10
39秒前
科研通AI2S的应助被季末默相依采纳,获得10
41秒前
41秒前
qiuy发布了新的文献求助10
41秒前
Arctic完成签到 ,获得积分10
41秒前
Justtry完成签到,获得积分10
43秒前
英姑的应助被thchiang采纳,获得10
43秒前
44秒前
苗条的访冬完成签到 ,获得积分10
46秒前
dyy完成签到 ,获得积分10
49秒前
Heaven完成签到 ,获得积分10
49秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808758
捐赠科研通 7776098
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012